Compare ClearPoint Neuro Inc (CLPT) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Plby Group Inc — how do they compare? ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M), while Plby Group Inc trades at $1.17 (market cap $136.40M). The key difference: ClearPoint Neuro Inc is far larger — about 3.5× Plby Group Inc's market cap, and ClearPoint Neuro Inc is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | PLBY | |
|---|---|---|
Market Cap | $478.63M | $136.40M |
Sector | Health | Consumer Cyclical |
52-Week High | $29.60 | $2.71 |
52-Week Low | $8.66 | $1.14 |
Enterprise Value | $506.63M | $284.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
PLBY trades at $1.17, up 0.86% today, but remains in a bearish technical trend. The company reported Q1 2026 revenue of $30.2 million with a narrowed net loss of $4.0 million, showing operational improvement. Recent news includes inclusion in Russell indexes and a major share repurchase. Despite negative ROE and high debt, analyst sentiment is positive with 75% buy ratings.
The outlook hinges on continued EBITDA growth and debt management. Opportunities include brand licensing momentum and cost controls. Key risks are persistent net losses, high leverage, and competitive pressures. Investors should weigh analyst optimism against fundamental challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
